Celgene Corporation (CELG): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.1%. By the end of trading, Celgene Corporation fell $4.91 (-2.9%) to $164.90 on heavy volume. Throughout the day, 7,678,957 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,658,000 shares. The stock ranged in price between $163.03-$174.66 after having opened the day at $170.47 as compared to the previous trading day's close of $169.81. Other companies within the Health Care sector that declined today were: Intercept Pharmaceuticals ( ICPT), down 18.3%, Conatus Pharmaceuticals ( CNAT), down 17.3%, Geron Corporation ( GERN), down 13.8% and Corcept Therapeutics ( CORT), down 13.1%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $69.5 billion and is part of the drugs industry. The company has a P/E ratio of 48.5, above the S&P 500 P/E ratio of 17.7. Shares are up 0.5% year to date as of the close of trading on Friday. Currently there are 22 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, IsoRay ( ISR), up 75.6%, Rexahn Pharmaceuticals ( RNN), up 40.4%, Oragenics ( OGEN), up 32.4% and Hemispherx Biopharma ( HEB), up 24.1% , were all gainers within the health care sector with Alnylam Pharmaceuticals ( ALNY) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks